DK0864646T3 - Fremgangsmåde til inaktivering af kappevira - Google Patents

Fremgangsmåde til inaktivering af kappevira

Info

Publication number
DK0864646T3
DK0864646T3 DK98890036T DK98890036T DK0864646T3 DK 0864646 T3 DK0864646 T3 DK 0864646T3 DK 98890036 T DK98890036 T DK 98890036T DK 98890036 T DK98890036 T DK 98890036T DK 0864646 T3 DK0864646 T3 DK 0864646T3
Authority
DK
Denmark
Prior art keywords
viruses
virus
intact
structural integrity
inactivating
Prior art date
Application number
DK98890036T
Other languages
English (en)
Inventor
Friedrich Prof Dorner
Noel Barrett
Otfried Dr Kistner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of DK0864646T3 publication Critical patent/DK0864646T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98890036T 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af kappevira DK0864646T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0029997A AT405939B (de) 1997-02-24 1997-02-24 Verfahren zur inaktivierung von lipidumhüllten viren

Publications (1)

Publication Number Publication Date
DK0864646T3 true DK0864646T3 (da) 2006-11-20

Family

ID=3486870

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05112299.2T DK1637593T3 (da) 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af lipidomhyllede vira
DK98890036T DK0864646T3 (da) 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af kappevira

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05112299.2T DK1637593T3 (da) 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af lipidomhyllede vira

Country Status (7)

Country Link
US (1) US6136321A (da)
EP (2) EP1637593B1 (da)
JP (1) JPH10234362A (da)
AT (3) AT405939B (da)
DE (2) DE59813677D1 (da)
DK (2) DK1637593T3 (da)
ES (2) ES2270501T3 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016539A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Virus sendai recombinant
JP4540795B2 (ja) * 2000-03-10 2010-09-08 一般財団法人阪大微生物病研究会 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
AU2004264842B2 (en) * 2000-06-29 2008-01-10 Eli Lilly And Company Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
AU2008201523B2 (en) * 2000-06-29 2011-07-28 Eli Lilly And Company Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
AR030829A1 (es) * 2000-10-02 2003-09-03 Smithkline Beecham Biolog Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
JP2004511251A (ja) 2000-10-17 2004-04-15 インパス，　インコーポレイテッド 核酸増幅コントロール
US6524586B2 (en) 2001-05-18 2003-02-25 Albany Medical College Enhancement of oligomeric viral immunogenicity
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
AU2002322284A1 (en) * 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
ES2715496T3 (es) 2003-07-03 2019-06-04 Hdl Therapeutics Inc Métodos y aparatos para crear derivados de partículas de HDL con un contenido reducido de lípidos
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
WO2007008918A2 (en) * 2005-07-08 2007-01-18 Wayne State University Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628158C (en) * 2005-11-04 2015-12-15 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
RU2496519C2 (ru) * 2007-08-28 2013-10-27 Бакстер Интернэшнл Инк. Способ получения препарата, содержащего вирусные антигены, и применение препарата
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
KR102238133B1 (ko) * 2013-11-15 2021-04-09 제넨테크, 인크. 환경-친화적 세제를 사용한 바이러스 불활성화 방법
US10821133B2 (en) 2017-12-28 2020-11-03 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN111511395B (zh) * 2017-11-03 2024-10-15 武田疫苗股份有限公司 用于将寨卡病毒灭活和用于确定灭活完全性的方法
CN118594035A (zh) 2017-11-22 2024-09-06 Hdl治疗公司 用于对血浆处理系统的流体回路进行灌注的系统和方法
JP2021505549A (ja) * 2017-11-30 2021-02-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカワクチン及び免疫原性組成物、ならびにその使用方法
CA3085885A1 (en) * 2017-12-19 2019-06-27 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
MX2022006987A (es) * 2019-12-12 2022-07-13 Lilly Co Eli Metodos para la inactivacion viral mediante detergentes compatibles con el medioambiente.
WO2022003565A1 (en) * 2020-07-01 2022-01-06 Medimmune, Llc Detergent and method for purifying a biotherapeutic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164565A (en) * 1975-03-14 1979-08-14 New York Blood Center, Inc. Vaccine for active immunization containing hepatitis B surface antigen and associated antigen
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4673733A (en) 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
DK0596032T4 (da) * 1991-07-25 2004-07-26 Idec Pharma Corp Induktion af cytotoksiske T-lymfocytsvar
DE4211108A1 (de) * 1992-04-03 1993-10-07 Boehringer Mannheim Gmbh Viruslösung zum Einsatz bei Immunoassays
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
ES2270501T3 (es) 2007-04-01
DE59813677D1 (de) 2006-09-21
US6136321A (en) 2000-10-24
EP0864646B1 (de) 2006-08-09
EP1637593A1 (de) 2006-03-22
JPH10234362A (ja) 1998-09-08
EP1637593B1 (de) 2010-08-18
ATE478138T1 (de) 2010-09-15
EP0864646A2 (de) 1998-09-16
ATA29997A (de) 1999-05-15
ES2350109T3 (es) 2011-01-18
DE59814464D1 (de) 2010-09-30
AT405939B (de) 1999-12-27
EP0864646A3 (de) 2002-05-15
ATE335810T1 (de) 2006-09-15
DK1637593T3 (da) 2010-11-22

Similar Documents

Publication Publication Date Title
DK0864646T3 (da) Fremgangsmåde til inaktivering af kappevira
ES511668A0 (es) "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante".
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
HK1009980A1 (en) Method for selective inactivation of viral replication
ES2191663T3 (es) Virus recombinante de la viruela porcina.
CO4810339A1 (es) Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion
AU6790087A (en) Modification of plant viruses or their effects
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
ES2058418T3 (es) Preparacion farmaceutica contra enfermedades viricas que comprende un extracto de higado.
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
NO971495L (no) Svekkede virus og fremgangsmåte til deres fremstilling
AR001399A1 (es) Una composición acondicionadora del cabello.
NO940810L (no) Behandling av virusinfeksjoner
DE69822542D1 (de) Verkapslung einer Untereinheit des Bovinen Herpes Virus Typ-1 in wässrigen Lösungsmitteln als Impfstoff.
DK0630408T3 (da) Fremstilling af $i(Aspergillus niger catalase-R)
DE3853672D1 (de) Nichtzurückschlagende RNS-Viren.
PT88430A (pt) Vecteur d'expression des proteines du virus hiv-2 un agent causal du sida culture cellulaire infectee ou transformee par ce vecteur procede de preparation de proteines et d'un vaccin et anticorps obtenus
DK0953088T3 (da) Bærekonstruktion og dennes konstruktionselementer
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
BR0009221A (pt) Vetores virais de inseto e usos dos mesmos
ATE318893T1 (de) Verbesserte replikation von hcv rna
FI893346A0 (fi) Icke-reverterande rna-virus.
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem
DE59410140D1 (de) Rinderovarzellinie (FROv) zur Virusvermehrung